[CAS NO. 57818-44-7] ABTL-0812

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [57818-44-7]

Catalog

HY-U00141

Brand

MCE

CAS

57818-44-7

DESCRIPTION [57818-44-7]

Overview

MDL	-
Molecular Weight	296.44
Molecular Formula	C18H32O3
SMILES	CCCCC/C=C\C/C=C\CCCCCCC(O)C(O)=O

For research use only. We do not sell to patients.

Summary

ABTL-0812 (α-Hydroxylinoleic acid) induces endoplasmic reticulum (ER) stress-mediated autophagy . ABTL-0812 is a first-in-class small molecule with anti-cancer activity ^[1] .

In Vitro

ABTL-0812 (ABTL0812; 10-100 μM; 48 hours) inhibits cell viability of squamous NSCLC H157 cells ^[1] .
Compared with squamous NSCLC H157 cells, human lung fibroblast cell line MRC-5 are resistant to ABTL0812 treatment ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[1]

Cell Line:	Human lung fibroblast MRC5 and squamous non-small cell lung (NSCLC) H157 cells
Concentration:	10, 30, 100 μM
Incubation Time:	48 hours
Result:	Inhibited cell viability of squamous NSCLC H157 cells, not lung fibroblast cell line MRC-5.

In Vivo

ABTL-0812 (ABTL0812; 120 mg/kg; oral gavage; 5 times per week; for 33 d) induces ER stress in human lung and pancreatic xenografts ^[1] .
ABTL-0812 induces hallmarks of ER stress in vivo. ABTL-0812 increases ATF4 and HSPA5 expression in mice bearing MiaPaca2 and A549 xenograft, respectively ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic female nude mice bearing MiaPaca2 and A549 xenograft models ^[1]
Dosage:	120 mg/kg
Administration:	Administered by oral gavage; 5 times per week for 33 days
Result:	Induced ER stress in human lung and pancreatic xenografts.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03366480	Ability Pharmaceuticals SL\|Hospital Vall d´Hebron\|Institut Català d´Oncologia\|Hospital Clínico Universitario de Valencia\|Hospitales Universitarios Virgen del Rocío\|Centre Leon Berard\|Institut Paoli-Calmettes\|Gustave Roussy, Cancer Campus, Grand Paris	Endometrial Cancer\|Squamous Non-Small Cell Lung Cancer	December 1, 2016	Phase 1\|Phase 2
NCT04431258	Ability Pharmaceuticals SL	Pancreatic Cancer	May 6, 2021	Phase 1\|Phase 2
NCT02201823	Ability Pharmaceuticals SL\|Hospital Clinic of Barcelona\|Institut Català d´Oncologia	Cancer	February 2014	Phase 1
NCT03417921	Ability Pharmaceuticals SL\|The Cleveland Clinic	Pancreatic Cancer	December 1, 2020	Phase 1\|Phase 2

Appearance

Liquid

Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL ( 843.34 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3734 mL	16.8668 mL	33.7336 mL
5 mM	0.6747 mL	3.3734 mL	6.7467 mL
10 mM	0.3373 mL	1.6867 mL	3.3734 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (7.02 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (7.02 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (7.02 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Muñoz-Guardiola P, et al. The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells. Autophagy. 2020 May 13.

Synonyms

9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-

9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-

(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid

α-Hydroxylinoleic acid

2-Hydroxylinoleic acid